Inositec is pioneering the development of life-saving small molecule drugs based on inositol phosphate, a natural facilitator of diverse cellular functions. Using its broadly applicable Inositune™ technology, Inositec modifies the chemical and physical properties of inositol phosphate (IP6) analogs to create a novel class of drugs targeting calcification disorders. Its lead compound, INS-3001, is a cardiovascular calcification inhibitor in development for aortic valve stenosis.

Founded in December 2015 based on award-winning research by Dr. Mattias Ivarsson, Prof. Jean-Christophe Leroux, and Prof. Bastien Castagner at ETH Zurich, Switzerland, Inositec was initially seeded by VI Partners alongside a small syndicate of local investors. VI Partners became a significant shareholder, with investment manager Arnd Kaltofen working closely with Mattias and his team.

In 2021, Vifor Pharma acquired the company for an upfront payment of CHF 20 million, with milestone-based clinical earn-out payments in the low triple-digit million range. VI Partners is proud to have played an instrumental role in Inositec’s journey.